Literature DB >> 35013530

Driver mutations in ADGRL3 are involved in the evolution of ependymoma.

Jing Wang1, Shao-Yan Xi2, Qi Zhao3, Yun-Fei Xia4, Qun-Ying Yang5, Hai-Ping Cai5, Fang Wang6, Yi-Ying Zhao5, Huan-Jing Hu3, Zhi-Hui Yu5, Fu-Rong Chen5, Peng-Fei Xu5, Ri-Zhen Xu5, Jian Wang5, Ji Zhang5, Chao Ke5, Xiang-Heng Zhang5, Fu-Hua Lin5, Cheng-Cheng Guo5, Yan-Chun Lv7, Cong Li5,8, Hai-Tao Xie8, Qian Cui9, Hong-Mei Wu9, Yan-Hui Liu9, Zhi Li9, Hong-Kai Su5, Jing Zeng2, Fu Han8, Zhao-Jie Li10, Ke Sai11, Zhong-Ping Chen12.   

Abstract

Although there have been recent advances in the molecular pathology of ependymomas, little is known about the underlying molecular evolution during its development. Here, we assessed the clinical, pathological and molecular evolutionary process of ependymoma recurrence in a 9-year-old patient who had seven recurrences of supratentorial ependymoma and died from intracranial multiregional recurrences at the age of 19 years old. Whole-genome sequencing (WGS) of 7 tumor samples (1 primary and 6 subsequent recurrent tumors) was performed to elucidate the mutation landscape and identify potential driver mutations for tumor evolution. The genetic profiles of the seven tumor specimens showed significant heterogeneity and suggested a highly branched evolutionary pattern. The mutational signatures and chromothripsis changed with treatments. Strikingly, adhesion G protein-coupled receptor L3 (ADGRL3, also known as Latrophilins 3, LPNH3) was found to be consistently mutated during the entire disease process. However, Sanger sequencing of other 78 ependymoma patients who underwent surgery at our institution showed no genetic alteration of ADGRL3, as found in the present case. The mRNA levels of ADGRL3 were significantly lower in ependymomas (n = 36), as compared with normal brain tissue (n = 3). Grade III ependymomas had the lowest ADGRL3 expression. Moreover, ependymomas with lower mRNA level of ADGRL3 had shorter overall survival. Our findings, therefore, demonstrate a rare evolutionary process of ependymoma involving ADGRL3.
© 2022. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35013530     DOI: 10.1038/s41374-021-00721-3

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.502


  45 in total

1.  Tracing the steps of cancer evolution.

Authors:  Conor A Bradley
Journal:  Nat Rev Urol       Date:  2018-07       Impact factor: 14.432

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.

Authors:  Kristian W Pajtler; Hendrik Witt; Martin Sill; David T W Jones; Volker Hovestadt; Fabian Kratochwil; Khalida Wani; Ruth Tatevossian; Chandanamali Punchihewa; Pascal Johann; Jüri Reimand; Hans-Jörg Warnatz; Marina Ryzhova; Steve Mack; Vijay Ramaswamy; David Capper; Leonille Schweizer; Laura Sieber; Andrea Wittmann; Zhiqin Huang; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Daniel Fults; Helen Toledano; Smadar Avigad; Lindsey M Hoffman; Andrew M Donson; Nicholas Foreman; Ekkehard Hewer; Karel Zitterbart; Mark Gilbert; Terri S Armstrong; Nalin Gupta; Jeffrey C Allen; Matthias A Karajannis; David Zagzag; Martin Hasselblatt; Andreas E Kulozik; Olaf Witt; V Peter Collins; Katja von Hoff; Stefan Rutkowski; Torsten Pietsch; Gary Bader; Marie-Laure Yaspo; Andreas von Deimling; Peter Lichter; Michael D Taylor; Richard Gilbertson; David W Ellison; Kenneth Aldape; Andrey Korshunov; Marcel Kool; Stefan M Pfister
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

4.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

5.  Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.

Authors:  Catherine Godfraind; Joanna M Kaczmarska; Mehmet Kocak; James Dalton; Karen D Wright; Robert A Sanford; Fredrick A Boop; Amar Gajjar; Thomas E Merchant; David W Ellison
Journal:  Acta Neuropathol       Date:  2012-04-21       Impact factor: 17.088

6.  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.

Authors:  S C Mack; H Witt; R M Piro; L Gu; S Zuyderduyn; A M Stütz; X Wang; M Gallo; L Garzia; K Zayne; X Zhang; V Ramaswamy; N Jäger; D T W Jones; M Sill; T J Pugh; M Ryzhova; K M Wani; D J H Shih; R Head; M Remke; S D Bailey; T Zichner; C C Faria; M Barszczyk; S Stark; H Seker-Cin; S Hutter; P Johann; S Bender; V Hovestadt; T Tzaridis; A M Dubuc; P A Northcott; J Peacock; K C Bertrand; S Agnihotri; F M G Cavalli; I Clarke; K Nethery-Brokx; C L Creasy; S K Verma; J Koster; X Wu; Y Yao; T Milde; P Sin-Chan; J Zuccaro; L Lau; S Pereira; P Castelo-Branco; M Hirst; M A Marra; S S Roberts; D Fults; L Massimi; Y J Cho; T Van Meter; W Grajkowska; B Lach; A E Kulozik; A von Deimling; O Witt; S W Scherer; X Fan; K M Muraszko; M Kool; S L Pomeroy; N Gupta; J Phillips; A Huang; U Tabori; C Hawkins; D Malkin; P N Kongkham; W A Weiss; N Jabado; J T Rutka; E Bouffet; J O Korbel; M Lupien; K D Aldape; G D Bader; R Eils; P Lichter; P B Dirks; S M Pfister; A Korshunov; M D Taylor
Journal:  Nature       Date:  2014-02-19       Impact factor: 49.962

Review 7.  cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.

Authors:  David W Ellison; Kenneth D Aldape; David Capper; Maryam Fouladi; Mark R Gilbert; Richard J Gilbertson; Cynthia Hawkins; Thomas E Merchant; Kristian Pajtler; Sriram Venneti; David N Louis
Journal:  Brain Pathol       Date:  2020-06-23       Impact factor: 7.611

Review 8.  The causes and consequences of genetic heterogeneity in cancer evolution.

Authors:  Rebecca A Burrell; Nicholas McGranahan; Jiri Bartek; Charles Swanton
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

Review 9.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.